271 related articles for article (PubMed ID: 18714001)
1. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes.
Watanabe S; Deguchi K; Zheng R; Tamai H; Wang LX; Cohen PA; Shu S
J Immunol; 2008 Sep; 181(5):3291-300. PubMed ID: 18714001
[TBL] [Abstract][Full Text] [Related]
2. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
Greifenberg V; Ribechini E; Rössner S; Lutz MB
Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
[TBL] [Abstract][Full Text] [Related]
5. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
Aruga A; Aruga E; Cameron MJ; Chang AE
J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
[TBL] [Abstract][Full Text] [Related]
6. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
Peng L; Kjaergäard J; Plautz GE; Awad M; Drazba JA; Shu S; Cohen PA
J Immunol; 2002 Nov; 169(9):4811-21. PubMed ID: 12391191
[TBL] [Abstract][Full Text] [Related]
7. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
8. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
Li H; Han Y; Guo Q; Zhang M; Cao X
J Immunol; 2009 Jan; 182(1):240-9. PubMed ID: 19109155
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
10. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
11. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
Plautz GE; Mukai S; Cohen PA; Shu S
J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
[TBL] [Abstract][Full Text] [Related]
12. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
[TBL] [Abstract][Full Text] [Related]
13. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
14. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site.
Haverkamp JM; Crist SA; Elzey BD; Cimen C; Ratliff TL
Eur J Immunol; 2011 Mar; 41(3):749-59. PubMed ID: 21287554
[TBL] [Abstract][Full Text] [Related]
15. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
Tanaka H; Tanaka J; Kjaergaard J; Shu S
J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
[TBL] [Abstract][Full Text] [Related]
16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of myeloid-derived suppressor cell subpopulations during the development of experimental arthritis.
Wang W; Jiao Z; Duan T; Liu M; Zhu B; Zhang Y; Xu Q; Wang R; Xiong Y; Xu H; Lu L
Eur J Immunol; 2015 Feb; 45(2):464-73. PubMed ID: 25352399
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression.
Tsukamoto H; Nishikata R; Senju S; Nishimura Y
Cancer Immunol Res; 2013 Jul; 1(1):64-76. PubMed ID: 24777249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
